A 12-week, randomized, double-blind, multi-center, vehicle-controlled, parallel group study to assess the efficacy and safety of the diclofenac sodium gel 1% (DSG 1%) for the relief of signs and symptoms in subjects with OA of the knee.

Trial Profile

A 12-week, randomized, double-blind, multi-center, vehicle-controlled, parallel group study to assess the efficacy and safety of the diclofenac sodium gel 1% (DSG 1%) for the relief of signs and symptoms in subjects with OA of the knee.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2012

At a glance

  • Drugs Diclofenac (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 Apr 2012 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 20 Apr 2012 Actual initiation date (Aug 2004) added as reported by ClinicalTrials.gov.
    • 02 May 2009 Primary endpoint results presented at the Annual Scientific Meeting of the American Geriatrics Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top